Literature DB >> 3608625

In vitro susceptibility of Mycobacterium avium to a new macrolide (RU-28965).

M Casal, F Rodriguez, R Villalba.   

Abstract

The in vitro susceptibility of Mycobacterium avium to RU-28965 alone and in combination with rifampin, isoniazid, and sulfametoxipiridazine was studied by the agar dilution method. The synergistic effect of the RU-28965 with rifampin has been demonstrated. At a concentration of 16 micrograms/ml or lower of RU-28965, 100% of M. avium strains were inhibited. If 2 micrograms/ml of rifampin is added the MIC of RU-28965 is lowered to 0.25 microgram/ml.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3608625     DOI： 10.1159/000238504

Source DB:  PubMed          Journal:  Chemotherapy        ISSN： 0009-3157            Impact factor:   2.544


  7 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 3.  Antimycobacterial susceptibility testing: present practices and future trends.

Authors:  C B Inderlied
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

4.  In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs.

Authors:  N Rastogi; K S Goh; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice.

Authors:  L Struillou; Y Cohen; N Lounis; G Bertrand; J Grosset; J L Vildé; J J Pocidalo; C Perronne
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

6.  In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex.

Authors:  N Rastogi; K S Goh; P Ruiz; M Casal
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

7.  In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex.

Authors:  F Stauffer; O Dörtbudak; E Lahonik
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.